Nano Mobile Healthcare’s Board and its Parent Company Approve Share Exchange Reducing Total Shares Outstanding

NEW YORK--()--Nano Mobile Healthcare (OTCQB: VNTH), (“Nano Mobile” or the “Company”) has announced its board of directors has agreed to exchange common shares into preferred shares with Nanobeak LLC.

The Company entered into an exchange agreement (the “Exchange Agreement”) with its majority shareholder, Nanobeak, LLC (“Nanobeak”), pursuant to which Nanobeak exchanged 117,366,840 shares of the Company’s common stock, par value $0.001 (the “Common Stock”), in exchange for 23,473,368 shares of the Company’s Series A Convertible Preferred Stock, par value $0.001 (the “Series A Convertible Preferred”).

The 117,366,840 shares of the Company’s common stock have been returned to Treasury, which has materially reduced the total shares outstanding of Nano Mobile Healthcare.

The new preferred shares represent a new class of stock of which Nanobeak is the sole shareholder. Nanobeak will retain its voting rights as if it were a common shareholder. Given that there is no market for the preferred shares, Nanobeak has demonstrated its intentions as a long-term shareholder of the Company.

For more information, please view the August 25, 2015 8K filed with the SEC on www.sec.gov.

About Nano Mobile Healthcare, Inc.

Nano Mobile Healthcare - a mobile health technology company - is developing personalized and point-of-care screening using Apps based upon chemical sensing residing within a Bluetooth device that works with any smartphone, tablet or laptop. With its foundations in advanced nanotechnology, the Company’s first product, the Nano Mobile Health Sensor, which is in development, is the convergence of nano-electronics, bio-informatics, and wireless technology to create the next generation mobile health application. The Company has offices in New York City and Mountain View, CA. For more information, please visit us at http://nanomobilehealthcare.com/.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. Such forward-looking statements may also include statements, among other things, concerning the efficacy, safety and intended utilization of Nano Mobile Healthcare’s product candidates, the conduct and results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to differ materially include, among others, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Nano Mobile Healthcare may not obtain approval to market its product candidates, or outside financing may not be available to meet capital requirements. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee.

For a further list and description of the risks and uncertainties the Company faces, please refer to the Company’s most recent Annual Report on Form 10-K and other periodic and other filings Nano Mobile Healthcare files with the Securities and Exchange Commission and are available at http://www.sec.gov/. Such forward-looking statements are current only as of the date they are made, and Nano Mobile Healthcare assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

CSIR Group, LLC.
Christine J. Petraglia, 212-386-7082
investors@csirgroup.com

Website

Nano Mobile Healthcare